Skip to main content
Clinical Trials/JPRN-jRCTc030200089
JPRN-jRCTc030200089
Suspended
Phase 1

A clinical study on the immunological effect of the preventive immune-cell therapy (abT) against high risk group of cancer

Takimoto Rishu0 sites20 target enrollmentAugust 20, 2020

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
Takimoto Rishu
Enrollment
20
Status
Suspended
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 20, 2020
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Takimoto Rishu

Eligibility Criteria

Inclusion Criteria

  • (1\)Have risk factors for cancer and desire for receiving the preemptive immune\-cell therapy.
  • (2\)Be \> 20 of age when obtaining the informed consent.
  • (3\)Be determined to be appropriate by the doctor in charge.
  • (4\)Provide written informed consent.

Exclusion Criteria

  • (1\)Be diagnosed with cancer.
  • (2\)Desire to receive the immune\-cell therapy for the treatment of any allergic disease.
  • (3\)Be HIV or HTLV\-1 positive.
  • (4\)Be an allotransplant recipient.
  • (5\)Have a history or sign of interstitial pneumonia.
  • (6\)Have an active autoimmune disease.
  • (7\)Be a female who is pregnant, nursing, or of childbearing potential.
  • (8\)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study.
  • (9\)Be determined to be inappropriate by the doctor in charge.

Outcomes

Primary Outcomes

Not specified

Similar Trials